NeurogesX Inc. (NeurogesX), is a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pains management therapies to address unmet medical needs. Qutenza is the Company's first commercial product, available in the United States and in certain European countries. Qutenza is a dermal delivery system designed to topically administer capsaicin to treat certain neuropathic pain conditions and was approved by the food and drugs administration (FDA) for the management of neuropathic pain associated with postherpetic neuralgia (PHN). Qutenza is also approved in the European Union for the treatment of peripheral neuropathic pain in non-diabetic adults. The Company's advanced drug candidate is NGX-1998. NGX-1998 is a topical liquid formulation of high concentration capsaicin that the Company is developing to treat neuropathic pain conditions.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
Phone+1-650-3583300
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
NeurogesX (OTCMKTS:NGSX) Frequently Asked Questions
What is NeurogesX's stock symbol?
NeurogesX trades on the OTCMKTS under the ticker symbol "NGSX."
Has NeurogesX been receiving favorable news coverage?
Headlines about NGSX stock have been trending negative on Sunday, InfoTrie reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. NeurogesX earned a news sentiment score of -2.1 on InfoTrie's scale. They also gave news coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for NeurogesX.
What is NeurogesX's stock price today?
One share of NGSX stock can currently be purchased for approximately $0.01.
What is NeurogesX's official website?
How can I contact NeurogesX?
NeurogesX's mailing address is 2215 Bridgepointe Pkwy Ste 200, FOSTER CITY, CA 94404-5067, United States. The specialty pharmaceutical company can be reached via phone at +1-650-3583300.
MarketBeat Community Rating for NeurogesX (OTCMKTS NGSX)
MarketBeat's community ratings are surveys of what our community members think about NeurogesX and other stocks. Vote "Outperform" if you believe NGSX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NGSX will underperform the S&P 500 over the long term. You may vote once every thirty days.
